scPharmaceuticals Inc. - Common Stock (SCPH)

Let's explore the current happenings on the US markets on Friday. Below, you'll find the stocks exhibiting unusual volume in today's session.

The deal hands MannKind access to scPharma’s Furoscix heart and kidney therapy, a product with a U.S. market potential estimated at over $10 billion.

MannKind will acquire scPharmaceuticals in a $360 million deal, adding Furoscix and expanding into cardiometabolic care with a $10 billion U.S. market opportunity.

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals.

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

SCPH stock results show that scPharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

FDA approves scPharmaceuticals' expanded Furoscix indication to include NYHA Class IV heart failure patients. scPharmaceuticals secures $125M non-dilutive financing to repay debt and advance commercialization. SCP-111 PK study shows 107.3% bioavailability, with favorable safety outcomes.

Panic can be a cruel emotion, especially when the consequences are uncapped red ink.

SCPH stock results show that scPharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.